(MENAFN- PR Newswire)
NEW YORK, June 10, 2024 /PRNewswire/ -- The global herpes treatment market size is estimated to grow by USD 1.14 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over
4.43% during the forecast period. Increasing prevalence of herpes infection
is driving market growth,
with a trend towards
emergence of novel therapies. However,
highly genericized market poses a challenge. Key market players include AbbVie Inc., AiCuris Anti infective Cures AG, Aurobindo Pharma Ltd., Avet Pharmaceuticals Inc., Bausch health Companies Inc., CENTURION REMEDIES Pvt. Ltd., Cipla Inc., Eli Lilly and Co., Fresenius SE and Co. KGaA, Gilead Sciences Inc., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Zeelab Laboratories Ltd., and Zydus Lifesciences Ltd..
Continue Reading
Technavio has announced its latest market research report titled Global herpes treatment market 2024-2028
Get a detailed analysis on regions, market segments, customer landscape, and companies
- View the snapshot of this report
| Forecast period |
2024-2028 |
| Base Year |
2023 |
| Historic Data |
2018 - 2022 |
| Segment Covered |
Product (Vaccination and Drug therapy), Type (Herpes zoster and Herpes simplex), and Geography (North America, Europe, Asia, and Rest of World (ROW)) |
| Region Covered |
North America, Europe, Asia, and Rest of World (ROW) |
| Key companies profiled |
AbbVie Inc., AiCuris Anti infective Cures AG, Aurobindo Pharma Ltd., Avet Pharmaceuticals Inc., Bausch Health Companies Inc., CENTURION REMEDIES Pvt. Ltd., Cipla Inc., Eli Lilly and Co., Fresenius SE and Co. KGaA, Gilead Sciences Inc., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Zeelab Laboratories Ltd., and Zydus Lifesciences Ltd. |
Key Market Trends Fueling Growth
The herpes treatment market faces a significant reliance on a restricted range of therapies, primarily managing genital and oral herpes outbreaks without curing the disease. Research is ongoing to introduce innovative treatments, such as Genocea's GEN-003 vaccine, which controls both shedding and outbreaks of HSV-2 infection.
Clinical trials are underway for this therapeutic vaccine, which is effective only for those already infected. Prevention trials are also being considered. The emergence of these novel therapies will enhance the treatment landscape for herpes, driving market growth during the forecast period.
The herpes treatment market is experiencing significant growth, with a focus on oral and genital herpes infections. Drugs such as Valacyclovir, Vaccines, and Antivirals are in high demand. Hospitals and research centers are investing in new treatments and therapies, including Famiclovir and Aciclovir. The use of zoster and acyclovirx in herpes treatment is also gaining traction.
The market is driven by the increasing number of people diagnosed with herpes and the need for effective treatment options. The market is competitive, with major players focusing on innovation and expanding their product portfolios. The use of sitavig and other topical treatments is also on the rise. Overall, the herpes treatment market is expected to continue growing due to the increasing prevalence of the disease and the development of new treatment options.
Research report provides comprehensive data on impact of trend. For more details-
Download a Sample Report
Market
Challenges
The herpes treatment market experiences high generic penetration due to patent
expiries and governmental support. This trend has led to price competition, decreasing revenue for branded drug vendors. European countries and US states have implemented generic substitution policies, increasing generic usage and reducing pharmaceutical expenses. Prevalence of herpes virus has risen, driving antiviral treatment growth to 63.6%. However, the cost per episode has decreased from USD139.61 to USD98, challenging market expansion.
The herpes treatment market faces several challenges. Genetics and remedies are key areas of focus. The identification of specific genes related to herpes is crucial for developing effective treatments. However, the complexity of the virus makes it difficult to find a definitive cure. The use of vaccines and antiviral medicines is common, but resistance to these treatments is a growing concern.
Additionally, the high cost of these treatments and the lack of accessibility in developing countries pose significant challenges. The market is also impacted by regulatory requirements and ethical considerations. The need for continuous research and development is essential to overcome these challenges and provide effective solutions for herpes sufferers.
For more insights on driver and challenges
-
Download a Sample Report
Segment Overview
Product
1.1 Vaccination
1.2 Drug therapy
Type
2.1 Herpes zoster
2.2 Herpes simplex
Geography
3.1 North America
3.2 Europe
3.3 Asia
3.4 Rest of World (ROW)
1.1
Vaccination- The Herpes Treatment Market is experiencing significant growth due to the rising prevalence of herpes infections and the increasing awareness about available treatments. Antiviral drugs remain the primary treatment option, with popular brands like Aciclovir, Valacyclovir, and Famciclovir leading the market. Additionally, the emergence of alternative therapies, such as homeopathy and herbal remedies, is expanding the market's scope. Overall, the Herpes Treatment Market is expected to continue its steady expansion in the coming years, driven by increasing demand and advancements in treatment methods.
For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2018 - 2022) - Download a Sample Report
Research Analysis
The Herpes Treatment Market encompasses various interventions for managing Herpes Simplex Virus (HSV) infections, including antiviral drugs and vaccines. Genital herpes infections, caused by HSV-1 and HSV-2, are a significant focus in this market. Antiviral drugs, such as Acyclovir, Valacyclovir, and Famciclovir, are commonly used for treating both oral and genital herpes infections. Phase 1/2 clinical trials are ongoing for new treatments, including gene therapy and mRNA therapeutics, to address the unmet needs in herpes treatment.
Healthcare expenditure on herpes treatments continues to rise due to the high prevalence of these infections and the ongoing research and development efforts. HSV infections are caused by the Varicella-zoster viruses, which also cause Chickenpox and Shingles. The hospital population, particularly those with weakened immune systems, are at a higher risk for herpes infections and require specialized care. Saliva, vaginal secretion, and semen can all serve as transmission routes for HSV infections.
Market Research Overview
The Herpes Treatment Market encompasses a range of products and services designed to manage and alleviate the symptoms of herpes infections. These treatments include antiviral medications, topical creams, and supportive therapies. The market is driven by the rising prevalence of herpes infections worldwide, as well as the growing awareness and acceptance of these conditions.
Additionally, advancements in research and technology are leading to the development of new and more effective treatments. The market is segmented based on product type, distribution channel, and geography. The antiviral medications segment dominates the market due to their proven efficacy in reducing the severity and duration of herpes outbreaks. The market is expected to grow at a steady pace in the coming years, driven by increasing demand and innovation in the field.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
Product
Type
Herpes Zoster
Herpes Simplex
Geography
North America
Europe
Asia
Rest Of World (ROW)
7
Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:
[email protected]
Website:
SOURCE Technavio
MENAFN10062024003732001241ID1108318033
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.